# Glycine-to-aspartic acid mutation at codon 51 in Snca disrupts the synaptic localisation of α-synuclein and enhances its propensity for synucleinopathy

**Authors:** Stephen West, Ammar Natalwala, Karamjit Singh Dolt, Douglas J Lamont, Melanie McMillan, Kelvin Luk, Tomoji Mashimo, Tilo Kunath

PMC · DOI: 10.1093/braincomms/fcaf224 · 2025-06-06

## TL;DR

A mutation in the α-synuclein gene in rats reduces its presence at synapses and increases the risk of Parkinson's-like brain pathology.

## Contribution

The study introduces the first rat model with the G51D α-synuclein mutation and shows its role in synucleinopathy.

## Key findings

- The G51D mutation reduces α-synuclein localization at synapses in rat brains.
- Rats with the G51D mutation show increased formation of Parkinson's-like pathological structures after PFF injections.
- Proteomic analysis reveals synaptic dysfunction in G51D mutant rats.

## Abstract

Point mutations in the SNCA gene, which encodes α-synuclein (αSyn), are a known cause of familial Parkinson’s disease. The glycine-51-aspartic acid (G51D) mutation causes early-onset neurodegeneration with complex, wide-spread αSyn pathology. We used CRISPR/Cas9 gene editing to introduce the G51D point mutation into the endogenous rat Snca gene. Our goal was to investigate whether the G51D αSyn mutation gives rise to synucleinopathy and neurodegenerative phenotypes in rats. Co-localisation immunostaining studies with synaptic proteins revealed that αSynG51D protein fails to efficiently localise to synapses. Furthermore, biochemical isolation of synaptosomes from rat cortex demonstrated a significant depletion of αSyn in SncaG51D/+ and SncaG51D/G51D rats. Unbiased proteomic investigation of the cortex identified significant synaptic dysregulation in SncaG51D/G51D animals. Finally, we compared the propensity for synucleinopathy of Snca+/+ and SncaG51D/G51D rats by stereotaxically delivering αSyn pre-formed fibrils (PFFs) into the pre-frontal cortex. At an early time-point, 6 weeks post-injection, we observed discrete Lewy pathology-like structures positive for phosphoserine-129-αSyn (pS129-αSyn) only in SncaG51D/G51D brains. At 26 weeks post-injection of PFFs, SncaG51D/G51D brains exhibited intense, discrete pS129-αSyn-positive structures, while Snca+/+ brains exhibited diffuse pS129-αSyn immunostaining. In summary, G51D mutagenesis of the endogenous Snca rat gene caused reduced synaptic localisation of αSyn, proteomic evidence of early synaptic dysfunction, and enhanced propensity for αSyn pathology.

West and Natalwala et al. report on the first rat model with a Parkinson’s α-synuclein (αSyn) mutation. A single amino acid change of glycine-to-aspartic acid at codon 51 in the rat Snca gene results in a reduced localisation of αSyn to synapses and an increased propensity to acquire Lewy pathology.

Graphical Abstract

## Linked entities

- **Genes:** SNCA (synuclein alpha) [NCBI Gene 6622], SNCA (synuclein alpha) [NCBI Gene 6622]
- **Diseases:** Parkinson’s disease (MONDO:0005180), synucleinopathy (MONDO:0000510)
- **Species:** Rattus norvegicus (taxon 10116)

## Full-text entities

- **Genes:** Snca (synuclein alpha) [NCBI Gene 29219]
- **Diseases:** synucleinopathy (MESH:D000080874), synaptic dysfunction (MESH:C536122), Lewy (MESH:D018827), familial Parkinson's disease (MESH:D010300), neurodegeneration (MESH:D019636)
- **Chemicals:** pS129 (-)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116]
- **Mutations:** G51D

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12198753/full.md

---
Source: https://tomesphere.com/paper/PMC12198753